logo
#

Latest news with #FujifilmHoldings

Canon, Fujifilm face GE HealthCare's growing scope
Canon, Fujifilm face GE HealthCare's growing scope

Nikkei Asia

time2 days ago

  • Business
  • Nikkei Asia

Canon, Fujifilm face GE HealthCare's growing scope

TOKYO -- U.S.-based GE HealthCare Technologies has expanded its reach in Japan while wielding market-leading computed tomography (CT) scanners as well as diagnostic drugs, pushing local players Canon and Fujifilm Holdings to try to counter its substantially larger scale. GE HealthCare entered the field of surgical treatment with an acquisition in 2021 and was spun off from General Electric in January 2023. The company looks to expand further through the highly profitable diagnostic drug business -- radiopharmaceuticals in particular. Radioactive substances can be used to diagnose cancer and Alzheimer's disease as well as aid in providing treatment tailored to each patient.

Fujifilm to tap India's growing chip industry with new materials plant
Fujifilm to tap India's growing chip industry with new materials plant

Nikkei Asia

time06-05-2025

  • Business
  • Nikkei Asia

Fujifilm to tap India's growing chip industry with new materials plant

TOKYO -- Fujifilm Holdings will build a semiconductor materials factory in India to supply a chip project backed by the country's government, hoping to tap into a supply chain that is growing as high-tech production moves away from China. The Japanese company will acquire land for the plant in the western state of Gujarat this year and start construction as early as 2026. Fujifilm aims to have it operating around 2028.

Japan's Fujifilm rides US-China rift to land $3bn biopharma deal
Japan's Fujifilm rides US-China rift to land $3bn biopharma deal

Nikkei Asia

time22-04-2025

  • Business
  • Nikkei Asia

Japan's Fujifilm rides US-China rift to land $3bn biopharma deal

TOKYO -- Fujifilm Holdings announced on Tuesday that it has signed a contract worth more than $3 billion to manufacture biologic drugs in the U.S. for a major American pharmaceutical company. The 10-year deal with Regeneron Pharmaceuticals, which marks the largest publicly known manufacturing contract for biopharmaceuticals on record, comes as U.S. pharmaceutical companies are doubling down on domestic supply in response to economic security policies and tariff measures by U.S. President Donald Trump.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store